

NOVEL TARGET TO TREAT A METABOLIC DISEASE IN AN INDIVIDUAL

Prevention treatment of obesity

TYPE OF DEVELOPMENT

Drug

DESCRIPTION

This invention describes how the acute downregulation in a gene expression in liver by the use of antisense oligonucleotides prevents and/or ameliorates obesity and the associated metabolic complications.

Increased prevalence of obesity has led to the rise in the development of metabolic diseases such as diabetes, insulin resistance, dyslipidemia and liver disease. Nowadays, there is an urgent need of finding therapeutic targets for obesity and the associated co-morbidities.

This invention refers to the prevention and treatment of obesity and the associated metabolic disease through the downregulation of the expression of a target gene, which mainly expresses in liver.

INDICATION

Treatment of diet induced obesity and the associated metabolic disease.

NOVELTY/ADVANTAGE

- A single dose per week
- A single treatment for obesity and all the associated metabolic diseases.
- No liver damage has been reported



Universidad
del País Vasco
Euskal Herriko
Unibertsitatea

Research group:

Lipids & Liver

Main researcher:

Patricia Aspichueta Celaá

Contact:

Knowledge/Technology Transfer
Office, iproperty.otri@ehu.eus

IPR STATUS

European Patent

Application:

EP19762826

Priority date:

10/09/2018

Applicant:

University of the Basque
Country (EHU).

COOPERATION GOAL

Company interested in the
license and sponsored research